Altimmune (ALT) Interest Coverage Ratio (2010 - 2026)
Altimmune (ALT) posted quarterly Interest Coverage Ratio of 9.04 for Q1 2026, down 3.68% year-over-year from 9.38 in Q1 2025, and up 64.35% quarter-over-quarter from 25.34 in Q4 2025.
Altimmune (ALT) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Interest Coverage Ratio for 17 consecutive years, with 9.04 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 3.68% year-over-year to 9.04; the TTM figure through Mar 2026 stood at 36.12 (up 7.92% YoY), while the FY2025 annual figure was 32.57, down 3259.75% from the prior year.
- Interest Coverage Ratio advanced to 9.04 in Q1 2026 per ALT's latest filing, from 25.34 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 126.2 in Q4 2022 and bottomed at 24866.0 in Q4 2024.
- Historically, Interest Coverage Ratio has averaged 2521.63 across 5 years, with a median of 24.8 in 2023.
- On a YoY basis, Interest Coverage Ratio climbed as much as 107.83% in 2022 and fell as far as 21748.56% in 2022.
- Altimmune's Interest Coverage Ratio stood at 126.2 in 2022, then plunged by 13421.66% to 16811.5 in 2023, then slumped by 47.91% to 24866.0 in 2024, then jumped by 99.9% to 25.34 in 2025, then surged by 64.35% to 9.04 in 2026.
- Business Quant data shows ALT's Interest Coverage Ratio at 9.04 in Q1 2026, 25.34 in Q4 2025, and 13.98 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | -10.72 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.72 |
| Mar 31, 2026 | -9.04 |
| Dec 31, 2025 | -25.34 |
| Sep 30, 2025 | -13.98 |
| Jun 30, 2025 | -14.28 |
| Mar 31, 2025 | -8.72 |
| Dec 31, 2024 | -24,866.00 |
| Sep 30, 2024 | -5.95 |
| Jun 30, 2024 | -5.14 |
| Mar 31, 2024 | -1.78 |
| Dec 31, 2023 | -16,811.50 |
| Sep 30, 2023 | -94.31 |
| Jun 30, 2023 | -24.80 |
| Mar 31, 2023 | -217.59 |
| Dec 31, 2022 | 126.20 |
| Sep 30, 2022 | -386.75 |
| Jun 30, 2022 | -313.77 |
| Mar 31, 2022 | -194.99 |
| Dec 31, 2021 | 60.72 |
| Sep 30, 2021 | -2.37 |